Next-Generation Neuroscience Is Here

We believe there’s a better way to treat central nervous system (CNS) diseases. Current treatments are not enough: they’re slow to take effect, have low response rates, and cause undesirable side effects. Gate Neurosciences is dedicated to developing the next generation of therapies for hundreds of millions worldwide suffering from neuropsychiatric and cognitive disorders.

Brain Health, Reimagined

We're on a mission to answer the unmet needs of people living with CNS diseases by developing safe, potent, and rapid-acting therapies that address hallmark disease biology. Our therapeutic candidates are specifically designed to target underlying synaptic dysfunction to restore healthy and balanced brain signaling. We are developing novel mechanisms that represent a more direct approach to enhancing synaptic function and neuroplasticity compared to other next-generation rapid antidepressants. By rethinking what’s possible, we’re creating hope for better treatments and better lives.


Our leadership team, board of directors, and investors and key shareholders have devoted decades to the treatment of CNS conditions, giving us the deep expertise necessary for meaningful innovation.


  • Michael G. McCully

    Michael G. McCully

    President & CEO

  • Ronald M. Burch M.D

    Ronald M. Burch, M.D., Ph.D.

    Chief Medical Officer

  • Anantha Shekar M.D Image

    Anantha Shekhar, M.D., Ph.D.,

    Chief Scientific Officer

See All Leadership

Board of directors

  • Michael G. McCully

    Michael G. McCully

    Director, CEO

  • Derek A. Small

    Derek A. Small

    Executive Chairman

  • Sarah J. Schlesinger, M.D.

    Sarah J. Schlesinger, M.D.


Investors and Key Shareholders

Powered by Precision

Our approach focuses on smarter neuroscience development. Robust translational insights and extensive clinical experience with our programs enable us to leverage precision medicine tools such as objective EEG biomarkers, patient responder analyses, and rigorous dose modeling combined with disciplined clinical execution to increase development success. As a result, our therapeutic candidates have maximum potential for patient impact. From neurodegenerative diseases to mood disorders, our platform offers a significant opportunity to more precisely address a broad set of diseases characterized by synaptic dysfunction.

See What’s Next in Neuroscience

We’re developing a growing portfolio of novel therapies for a broad range of neuropsychiatric and cognitive disorders.


Our lead development programs, Zelquistinel (oral) and Apimostinel (injectable), are potent next-generation NMDAR modulators that in Phase 2a studies demonstrated a well-tolerated safety profile and statistically significant effects on clinical measures of antidepressant efficacy. Both next-gen programs leverage key learnings from the first-generation NMDAR molecule, Rapastinel (GLYX-13), which demonstrated proof-of-concept across multiple clinical MDD studies in combined over 2,000 patients. Our novel NMDAR mechanism is designed as a more direct approach to enhancing synaptic function and neuroplasticity through the NMDA receptor, without causing dissociation, hallucination, or ketamine-like side effects. Recent publications by Donello, 2022, Lee, 2020,  and Duman, 2021, highlight this potent and differentiated mechanism versus NMDAR antagonists or channel blockers. Gate Neurosciences is planning to initiate confirmatory Phase 2 studies of Zelquistinel and Apimostinel in depressive disorders in 2023.

Contact Us


11711 North Meridian Street
Suite 310
Carmel, IN 46032
United States